WASHINGTON -- Freedom from relapse was maintained in multiple sclerosis patients on natalizumab (Tysabri) who received the infusion drug less frequently than the recommended 4-week interval, with ...
Please provide your email address to receive an email when new articles are posted on . Incidence rates for second through sixth cSCCs increased (28% to 67%), while time intervals decreased (1.4 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback